Key statistics
As of last trade Ascentage Pharma Group International (36X:FRA) traded at 4.92, -14.43% below its 52-week high of 5.75, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.10 |
---|---|
High | 5.10 |
Low | 4.92 |
Bid | 4.98 |
Offer | 5.15 |
Previous close | 4.92 |
Average volume | 80.22 |
---|---|
Shares outstanding | 315.20m |
Free float | 210.68m |
P/E (TTM) | -- |
Market cap | 13.36bn HKD |
EPS (TTM) | -1.34 HKD |
Data delayed at least 15 minutes, as of Nov 21 2024 08:15 GMT.
More ▼
Press releases
- Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
- Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
- ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
- ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
- Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
- Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
- ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
More ▼